Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Nuclear Medicine Radioisotopes Market Poised To Hit $12.75 Billion By 2030 With A 7.4% CAGR
The nuclear medicine radioisotopes market size has demonstrated robust expansion in recent years. This market is expected to expand from $8.85 billion in 2025 to $9.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The past growth can be ascribed to several factors, including the extensive application of technetium-99m in diagnostic imaging, the increasing uptake of nuclear cardiology procedures, the rising incidence of cancer and thyroid disorders, the growth of hospital-based nuclear medicine departments, and the early favorable outcomes of radioisotope-based therapies.
The nuclear medicine radioisotopes market size is anticipated to experience robust expansion over the coming years. This market is projected to reach $12.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. The projected growth during this period is primarily driven by several factors, including the increasing need for personalized cancer treatments, a surge in the application of lutetium-177 and actinium-225 therapies, the expanding infrastructure for PET imaging, rising investments in cyclotron and reactor facilities, and the increasing integration of nuclear medicine in developing countries. Key trends expected within this forecast timeframe encompass the increasing implementation of theranostics in cancer care, a growing demand for PET and SPECT imaging techniques, enhanced utilization of targeted alpha and beta emitters, the broadening application of nuclear medicine in cardiology and neurology, and a reinforced emphasis on localized radioisotope manufacturing.
Get A Free Sample Report With In-Depth Market Insights:
Nuclear Medicine Radioisotopes Market Development Factors: What’s Supporting Demand?
The increasing incidence of cardiovascular ailments is projected to drive the expansion of the nuclear medicine radioisotope market in the foreseeable future. These conditions encompass various illnesses impacting the heart and blood vessel system. The surge in cardiovascular disease cases is linked to inactive lifestyles, unhealthy eating patterns, growing obesity prevalence, and an aging demographic. Nuclear medicine radioisotopes play a crucial role in the diagnosis, assessment, and management of cardiovascular diseases, offering comprehensive data on cardiac function, blood flow, and tissue health, which is vital for precise diagnosis and successful treatment strategies. As an illustration, the American Heart Association, a US-based non-profit organization, reported in January 2024 that the age-adjusted mortality rate from cardiovascular disease escalated to 233.3 per 100,000 in 2024, representing a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the growing number of cardiovascular disease instances is fueling the expansion of the nuclear medicine radioisotope market.
Nuclear Medicine Radioisotopes Market Segmentation And Category Overview
The nuclear medicine radioisotopes market covered in this report is segmented –
1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types
2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
Subsegments:
1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging
3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)
4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging
5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging
6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment
7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment
8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment
9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)
10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)
Nuclear Medicine Radioisotopes Market Transformation Trends: What Innovations Are Driving Change?
Leading companies within the nuclear medicine radioisotopes market are concentrating on creating novel solutions, such as next-generation theranostic radiopharmaceuticals, aimed at improving precision imaging and targeted treatment. These advanced radioactive agents are engineered to both detect and precisely address diseases by accurately targeting particular cells within the body. For instance, in November 2025, the University of California, a US-based research university, established a fully autonomous Department of Nuclear Medicine & Theranostics, separating nuclear medicine from its previous inclusion under a wider radiology department. The purpose of this new department is to expedite the incorporation of sophisticated imaging techniques and targeted radiopharmaceutical treatments, while also reinforcing research, educational, and clinical initiatives to further precision medicine and foster advancements in theranostic therapies.
Nuclear Medicine Radioisotopes Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation
View The Full Nuclear Medicine Radioisotopes Market Report:
Nuclear Medicine Radioisotopes Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model